BCL2 and cancer: Nevertheless, the development of BH3 mimetics continued, resulting in ABT‐737 and its orally available successor ABT‐263 (navitoclax), as selective on‐target inhibitors of Bcl‐2, Bcl‐xL and Bcl‐w that are able to induce cancer cell death (Oltersdorf et al.,2005; Del Gaizo Moore et al.,2008).